SAB4200621
Monoclonal Anti-NG2/CSPG4 antibody produced in mouse
clone 2164B6, purified from hybridoma cell culture
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Kod UNSPSC:
12352203
NACRES:
NA.41
Polecane produkty
pochodzenie biologiczne
mouse
Poziom jakości
białko sprzężone
unconjugated
forma przeciwciała
purified immunoglobulin
rodzaj przeciwciała
primary antibodies
klon
2164B6, monoclonal
Postać
buffered aqueous solution
reaktywność gatunkowa
human
stężenie
~1 mg/mL
metody
flow cytometry: 2.5-5 μg/test using SK-Mel-28 cells.
immunofluorescence: 2.5-5 μg/mL using A375 cells.
izotyp
IgG1
numer dostępu UniProt
Warunki transportu
dry ice
temp. przechowywania
−20°C
docelowa modyfikacja potranslacyjna
unmodified
informacje o genach
human ... CSPG4(1464)
Opis ogólny
Nerve/glial antigen 2 (NG2), a high molecular mass melanoma- associated antigen (HMW-MAA), is a large integral membrane, cell surface type I transmembrane protein that is covalently modified with chondroitin sulfate glycosaminoglycan.
Immunogen
a recombinant extracellular portion of human NG2 proteoglycan
Zastosowanie
Monoclonal Anti-NG2/CSPG4 antibody produced in mouse used in flow cytometry and immunocytochemistry.
Działania biochem./fizjol.
Nerve/glial antigen 2 (NG2) plays a central role in linking multiple oncogenic pathways required for malignant progression. NG2 expression in radial growth phase (RGP) human melanomas enables migration, protease activation and epithelial to mesenchymal transition, which is important in primary tumors for facilitating progression from a radial to vertical growth phase phenotype. It regulates sustained, high-level activation of key survival and growth pathways, integrin-regulated focal adhesion kinase (FAK), extracellular signal-regulated kinases 1 and 2 (ERK 1,2) and phosphoinositide 3-kinase (PI3K)/AKT pathways.
Postać fizyczna
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Oświadczenie o zrzeczeniu się odpowiedzialności
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
This page may contain text that has been machine translated.
Not finding the right product?
Try our Narzędzie selektora produktów.
Kod klasy składowania
10 - Combustible liquids
Klasa zagrożenia wodnego (WGK)
WGK 1
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Megan S Lord et al.
The FEBS journal, 280(10), 2490-2510 (2013-02-20)
Proteoglycans are ubiquitous dynamic molecules that are made up of a protein core to which specific linear glycosylation structures, known as glycosaminoglycans, have been covalently coupled. They have roles in many biological and pathological processes, which have been shown to
X Wang et al.
Current molecular medicine, 10(4), 419-429 (2010-05-12)
Chondroitin sulfate proteoglycan 4 (CSPG4), also known as High Molecular Weight-Melanoma Associated Antigen, is a cell surface proteoglycan which has been recently shown to be expressed not only by melanoma cells, but also by various types of human carcinoma and
Matthew A Price et al.
Pigment cell & melanoma research, 24(6), 1148-1157 (2011-10-19)
Chondroitin sulfate proteoglycan 4 (CSPG4), a transmembrane proteoglycan originally identified as a highly immunogenic tumor antigen on the surface of melanoma cells, is associated with melanoma tumor formation and poor prognosis in certain melanomas and several other tumor types. The
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
Xinhui Wang et al.
Journal of the National Cancer Institute, 102(19), 1496-1512 (2010-09-21)
The cell surface proteoglycan, chondroitin sulfate proteoglycan 4 (CSPG4), is a potential target for monoclonal antibody (mAb)-based immunotherapy for many types of cancer. The lack of effective therapy for triple-negative breast cancer (TNBC) prompted us to examine whether CSPG4 is
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej